Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Corneal Trauma Diagnostic Study

NCT07887425 · tracked via the Priya Life Science USA tracker
Sponsor
InnSight Technology, Inc
Phase
Not applicable
Started
2026-11
Last updated
2026-10-21

Condition(s) studied

Ocular Trauma

Investigational drug(s) / intervention(s)

Tear fluid collection with mass spec analysis.

Tear fluid collection with mass spec analysis.: Tear fluid collection with mass spec analysis.

Study summary

Tear fluid will be collected from patients diagnosed with ocular trauma at the University of Pittsburgh Medical Center to evaluate biomarkers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Minimum age of 18 years. * Diagnosis of visually significant cataract and scheduled for routine cataract surgery at UPMC with a clear corneal incision or * scheduled for clinical repair of a full-thickness corneal laceration. Exclusion Criteria: * Prior history of full-thickness corneal laceration from trauma or from a surgical procedure * Current diagnosis of glaucoma or use of ocular hypotensive drops or oral aqueous suppressants. * Actively being treated for the diagnosis of dry eyes with a topical drop other than artificial tears. * Actively taking oral or topical supplementation of Vitamin C. * Scheduled for additional eye surgeries, combined with the routine cataract surgery. * Surgical plan that would include incisions in the clear for cataract extraction. * Inability to provide informed consent due to suspected head trauma, altered mental status, or other factors impairing decision-making capacity.

Primary outcome measure(s)

  • Primary Outcome - Ascorbic Acid — One year.
    Measurement of ascorbic acid using mass spec

Trial sites (1)

FacilityCityRegionStatus
UPMC Vision Insititute - Mercy Pavilion Pittsburgh Pennsylvania Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07887425 on ClinicalTrials.gov ↗ ← All trials in the USA